• WCG’s eCOA portfolio and imaging analysis technology from NeuroRx are now part of Clario!

menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
        • Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

        • Make your clinical trials easier, faster, more engaging and accessible to all.

        • Enjoy flexible, fast and confidential site assessments at home.

        • Enhance your ePRO data with photo and audio capture.

        • Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

        • Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

        • Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

        • Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Centralized, on-site pulmonary function testing for clinical trials.

        • Remote spirometry testing for respiratory clinical trials.

        • Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Assess the capacity of the lungs for effective gas transfer.

        • Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
    • Study Phases
    • Technology
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • Study Endpoints
      • Cardiac Solutions
        • Cardiac Solutions
        • Arrhythmia Analysis
        • Blood Pressure Services
        • ECG — On-site to DCT and Phase I-IV
        • Phase I/TQT Cardiac Assessment
        • Regulatory Consultation and Statistical Analysis Expertise
      • Clinical Adjudication
      • eCOA
        • eCOA Clinical Trials
        • eCOA Live
        • eCOA Multimedia
        • eCOA Rapid Start
        • eCOA Rater and Participant Training
        • eCOA Rescue Studies
        • Suicidal Ideation
      • Medical Imaging
        • Medical Imaging
        • Image Redact AI
        • Imaging Platform
        • Medical Imaging Science Team
        • Modalities
        • SMART Submit
      • Precision Motion
        • Precision Motion for Clinical Trials
        • Precision Motion for Research
        • Precision Motion: Scientific Publications
      • Respiratory Solutions
        • Respiratory Solutions
        • Site-Based Spirometry
        • Virtual Home Spirometry
        • Cough and Lung Sounds
        • Diffusing Capacity (DLCO)
      • Trial Enablement
        • Trial Enablement
        • Eligibility Solution
        • Reporting & Analytics
        • Source Document Manager
    • Segments
      • Biotechs
      • CROs
      • Pharma
    • Study Phases
      • Phase I
      • Phase II/III
    • Technology
      • Artificial Intelligence (AI)
      • Hybrid Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Diabetes and Obesity
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
      • Dementias
      • Headache Disorders
      • Movement Disorders
      • Multiple Sclerosis
      • Pain Disorders
      • Psychiatric Disorders
    • Oncology
    • Ophthalmology
    • Respiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home About Newsroom Clario extends leadership in real-world data collection through new partnership with ActiGraph, a leading activity tracking and wearable tech company

Clario extends leadership in real-world data collection through new partnership with ActiGraph, a leading activity tracking and wearable tech company

Collaboration will improve patient experience and study efficiency through wearable technology – while capturing a wider range of activity and sleep data

  • Clario will offer ActiGraph technologies to its customers to complement its suite of eCOA, Precision Motion, Cardiac Safety, Respiratory, Medical Imaging and Trial Enablement solutions 
  • Clario’s leading Precision Motion offering, the Opal V2C® system, delivers high-fidelity data and analytics that can accelerate study start-up timelines and deliver deeper insights into functional mobility. 
  • ActiGraph’s FDA-cleared, medical-grade wearable technology captures objective, real-world biometric data related to physical activity, mobility, sedentary behavior and sleep 
  • ActiGraph’s wearable technology enables clinical trial sponsors to increase the accuracy of continuous passive monitoring and quality of clinical data with real-time digital capture of objective endpoints related to activities of daily living and Quality of Life measures 

PHILADELPHIA, PA – June 16, 2022 – Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, today announced that it is partnering with ActiGraph, a pioneer and leading provider of activity-sensing wearable technology, to further expand its already broad evidence generation platform and portfolio of decentralization technologies. The partnership will help clinical trial sites and sponsors drive efficiency and accuracy while increasing convenience for study participants. Clario will offer ActiGraph technologies to its customers in addition to its suite of eCOA, Precision Motion, Cardiac Safety, Respiratory, Medical Imaging and Trial Enablement solutions.  

Quality of Life is increasingly seen as a critical patient reported outcome (PRO) by regulatory bodies as they seek evidence of how clinical interventions change the way patients feel overall. Consequently, activity-related endpoints are required in clinical studies across many therapeutic areas (including oncology, neuroscience, cardiovascular disease, diabetes, obesity and sleep disorders) where patients might be managing their conditions for a prolonged period. Historically, this requirement has imposed a burden on study participants who are asked to submit subjective patient reports. In contrast, ActiGraph’s FDA-cleared, medical-grade platform captures objective, real-world biometric data related to physical activity, mobility, sedentary behavior and sleep. With the proper data science and validation support from ActiGraph and Clario, these data can truly enable clinical trial sponsors to increase the precision, quality and completeness of clinical data by augmenting subjective patient reports and point-in-time clinical outcome data with continuous digital measures. 

“We are at an inflection point. Regulatory agencies and patients expect clinical interventions to extend quality, not just length of life,” said Ellen Street, EVP Cardiac Safety and Precision Motion at Clario. “Partnering with ActiGraph allows us to provide our customers with a wider range of measurable and meaningful patient Quality of Life endpoints and is the next step in how we aim to transform lives through technologies that generate the richest clinical evidence.”  

Ellen went on to say: “Quality of Life endpoints such as motion and sleep are best measured over extended periods of time and in a range of settings. Decentralized clinical trials can make best use of these endpoints and help bring life-enhancing therapies to market faster. We are proud to offer our customers another key technology that not only enables DCTs but also makes patient participation and site responsibilities less burdensome and activity-related data more precise.” 

Built on more than 20 years of real-world data capture expertise, ActiGraph’s fit-for-purpose ecosystem of wearable biosensors, software tools and scientific services delivers digital data in near real-time through a flexible cloud-based technology platform designed around the challenges and complexities of the clinical development process. ActiGraph’s technologies, combined with Clario’s depth of scientific expertise, global scale and existing ability to collect data across a wide range of endpoints, will help ensure complex global trials run smoothly, whether they are on-site, decentralized or hybrid.  

“The combination of high-fidelity wearable endpoints deployed on our CentrePoint platform with an industry-leading eCOA tool represents an opportunity to improve the patient experience in modern clinical trials,” said Jeremy Wyatt, CEO at ActiGraph. “The most accurate picture of a patient’s experience comes from a combination of self-reported and high-integrity, objective measurements. Our teams are excited to begin drawing upon Clario’s expertise and providing pharma and biotech companies with our technological and scientific resources, as we both work to advance the development of drugs and therapies.” 


About ActiGraph

Founded in 2004, ActiGraph is a leading wearable technology partner within the pharmaceutical and academic life science research industries. ActiGraph’s biosensor solutions have been deployed in hundreds of industry-sponsored clinical drug trials and continue to pave the way for real-world remote monitoring within this complex and highly regulated space. With well over 2,000 clients in more than 110 countries, and referenced in approximately 20,000 peer-reviewed articles, ActiGraph has earned its reputation as the “Gold Standard” in objective activity measurement. 

For more information, go to ActiGraphCorp.com or follow us on LinkedIn or Twitter.

About Clario

Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized and site-based trials, our deep scientific expertise, global scale, and the broadest endpoint technology platform in the industry, allows our partners to transform lives. Clario’s solutions have been powering hybrid and decentralized clinical trials (DCT) for over 15 years, enabling sponsors to collect high-quality endpoint data from any modality or location, all while improving the patient experience and diversity. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion and respiratory endpoints. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory for over 5m patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.

For more information, go to Clario.com or follow us on LinkedIn or Twitter. 

Clario Media Contact

Duncan Cantor
Sr. Director, Corporate Communications
[email protected]

Back to newsroom
Share
Twitter Facebook LinkedIn

Related News

See all news

Clario Announces Completion of Acquisition of WCG’s eCOA Business

May 6, 2025 Read more

Clario collaborates with AWS to push new boundaries in clinical data analysis with generative AI 

April 16, 2025 Read more

Clario announces acquisition of imaging provider NeuroRx

March 17, 2025 Read more
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum